Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Abeona Therapeutics Inc.NASDAQ: ABEO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q1 FY2026 financing cash flow was -$2.22M, compared with $6.77M a year earlier. Trailing-twelve-month financing cash flow was $17.05M. Over 3 fiscal years it compounded at -15.5% a year.
Context
- Financing cash flow amounted to 447.4% of revenue in FY2025.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$2.22M or moves back toward the trailing-twelve-month quarterly average of $4.26M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 26.04M USD
- Year-over-year change
- -75.0%
- 4-year CAGR
- +1.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.04M | -75.0% |
| FY2024 | 2024-12-31 | 104.14M | +181.0% |
| FY2023 | 2023-12-31 | 37.06M | -14.2% |
| FY2022 | 2022-12-31 | 43.17M | +73.7% |
| FY2021 | 2021-12-31 | 24.86M | — |
Financing Cash Flow vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 financing cash flow of $17.05M is the 7th largest of the 10 companies compared; the peer median is $38.07M.
- Its year-over-year change of -80.1% is the 9th highest of 10, against a peer median of -0.0%.
- Financing cash flow amounts to 117.3% of revenue for ABEO, versus a peer median of 179.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.89M | +451.1% | +557.7% | 243.2% | |
| LTM Mar 2026 | $57.73M | +12.7% | +11.7% | 25658.2% | |
| LTM Mar 2026 | $53.69M | -59.8% | — | — | |
| LTM Mar 2026 | $50.66M | -51.5% | -16.6% | 179.5% | |
| LTM Mar 2026 | $45.17M | -0.0% | — | 19.9% | |
| LTM Mar 2026 | $38.07M | -61.2% | — | 1888.3% | |
| LTM Mar 2026 | $17.05M | -80.1% | -15.5% | 117.3% | |
| LTM Mar 2026 | $4.07M | +227.6% | -9.7% | 11.1% | |
| LTM Mar 2026 | $1.8M | -109.8% | — | 4.0% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $275K | +1118.5% | — | — |
| Peer median (excluding ABEO) | $38.07M | -0.0% | +1.0% | 179.5% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.92M | 3.05M | 4.77M | 6.63M | 10.78M |
| Change in Working Capital | (18.26M) | (5.89M) | (1.79M) | (4.38M) | (5.39M) |
| Accounts Receivables | (3M) | 2.81M | (2.04M) | 792K | (5.06M) |
| Inventory | 0 | 0 | 0 | 0 | (5.49M) |
| Accounts Payables | (15.59M) | (9.11M) | 2.04M | (3.49M) | 6.54M |
| Other Working Capital | 324K | 404K | (3.83M) | (1.68M) | (1.37M) |
| Other Non-Cash Items | 24.15M | (5.52M) | 11M | 2.57M | (156.46M) |
| Operating Cash Flow | (65.67M) | (43.48M) | (37.01M) | (56.02M) | (76.33M) |
| Capital Expenditures | (4.15M) | (130K) | (331K) | (2.45M) | (7.98M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.16M) | (78.21M) | (51.64M) | (157.01M) | (206.63M) |
| Sales of Investments | 90.38M | 52.64M | 51.97M | 120.2M | 167.27M |
| Other Investing Activities | 0 | 1.73M | 204K | 18K | 152.37M |
| Investing Cash Flow | 66.06M | (23.96M) | 208K | (39.24M) | 105.03M |
| Debt Repayment | 0 | 0 | 0 | 20M | 0 |
| Common Stock Issued | 24.03M | 46.96M | 37.39M | 85.63M | 26.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 831K | (5K) | (332K) | (1.49M) | (37K) |
| Financing Cash Flow | 24.86M | 43.17M | 37.06M | 104.14M | 26.04M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.26M | (24.27M) | 256K | 8.88M | 54.74M |
| Free Cash Flow | (69.82M) | (43.61M) | (37.34M) | (58.46M) | (84.3M) |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.